COPD急性加重期患者上呼吸道菌群特征变化的研究

注册号:

Registration number:

ChiCTR2200066096 

最近更新日期:

Date of Last Refreshed on:

2023-08-10 16:14:15 

注册时间:

Date of Registration:

2022-11-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

COPD急性加重期患者上呼吸道菌群特征变化的研究

Public title:

Study on the characteristics of upper respiratory tract flora in patients with acute exacerbation of COPD

注册题目简写:

English Acronym:

研究课题的正式科学名称:

COPD急性加重期患者上呼吸道菌群特征变化的研究

Scientific title:

Study on the characteristics of upper respiratory tract flora in patients with acute exacerbation of COPD

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周宇麒 

研究负责人:

周宇麒 

Applicant:

Zhou Yuqi 

Study leader:

Zhou Yuqi 

申请注册联系人电话:

Applicant telephone:

+86 13533489943

研究负责人电话:

Study leader's
telephone:

+86 13533489943

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhouyuqi@mail.sysu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

zhouyuqi@mail.sysu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市天河区天河路600号

研究负责人通讯地址:

广东省广州市天河区天河路600号

Applicant address:

600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China

Study leader's address:

600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学附属第三医院

Applicant's institution:

The Third Affiliated Hospital of Sun Yat-sen University

研究负责人所在单位:

中山大学附属第三医院

Affiliation of the Leader:

The Third Affiliated Hospital of Sun Yat-sen University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2022]02-239-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属第三医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-10-11 00:00:00

伦理委员会联系人:

黄凯琪

Contact Name of the ethic committee:

Kaiqi Huang

伦理委员会联系地址:

广东省广州市天河区天河路600号

Contact Address of the ethic committee:

600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 8525 3302

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中山大学附属第三医院

Primary sponsor:

The Third Affiliated Hospital of Sun Yat-sen University

研究实施负责(组长)单位地址:

广东省广州市天河区天河路600号

Primary sponsor's address:

600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第三医院

具体地址:

广东省广州市天河区天河路600号

Institution
hospital:

The Third Affiliated Hospital of Sun Yat-sen University

Address:

600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China

经费或物资来源:

研究者自筹

Source(s) of funding:

Investigator's expense

研究疾病:

慢性阻塞性肺疾病  

Target disease:

Chronic obstructive pulmonary disease (COPD)

研究疾病代码:

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

通过16sRNA基因测序分析急性加重期、恢复期及稳定期COPD患者气道微生态的菌群构成特征,分析慢阻肺不同时期微生态的动态变化。  

Objectives of Study:

6sRNA gene sequencing was used to analyze the flora composition characteristics of airway microecology of COPD patients in acute exacerbation, recovery and stable stage, and to analyze the dynamic changes of microecology in different periods of COPD.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.排除口咽局部病变患者; 2.不能按要求随访收集咽拭子标本的患者。

Exclusion criteria:

1. Exclude patients with local lesions of oropharynx; 2. Patients who can't collect throat swabs can't be followed up as required.

研究实施时间:

Study execute time:

From 2022-12-01 00:00:00 To 2023-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-12-01 00:00:00 To 2023-01-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

30

Group:

experiment group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

对照组

样本量:

30

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第三医院 

单位级别:

三甲医院 

Institution
hospital:

The Third Affiliated Hospital of Sun Yat-sen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

呼吸道微生态

指标类型:

主要指标

Outcome:

Respiratory tract microecology

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Complete Blood Count

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床常规生化

指标类型:

主要指标

Outcome:

Clinical routine biochemistry

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

咽拭子

组织:

口腔

Sample Name:

Pharyngeal swab

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便标本

组织:

Sample Name:

Fecal specimen

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 45 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机。根据是否有慢性阻塞性肺疾病分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Non-random. According to whether there is chronic obstructive pulmonary disease. According to whether there is chronic obstructive pulmonary disease.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台ResMan(www.medresman.org)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical trial public management platform ResMan (www.medresman.org)..

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-11-24 10:51:33